Prevalence and risk of migraine headaches in adult fragile X premutation carriers

Clinical Genetics

Volumn 84, Issue 6, 2013, Pages 546-551

  Au, J ^a,b   Akins, R S ^c   Berkowitz Sutherland, L ^a,b   Tang, H T ^d   Chen, Y ^a,b   Boyd, A ^a,b   Tassone, F ^d   Nguyen, D V ^d   Hagerman, R ^a,b  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fragile X premutation; Fragile X tremor ataxia syndrome; Headaches; Migraine disorders

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIGRAINE; PHYSICAL EXAMINATION; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

FRAGILE X PREMUTATION; FRAGILE X TREMOR ATAXIA SYNDROME; HEADACHES; MIGRAINE DISORDERS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PREVALENCE; RISK; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84886788479     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12109     Document Type: Article

References (71)

1. Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008: 45 (8): 498-499.
2. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X et al. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009: 11 (4): 324-329.
3. Seltzer MM, Baker MW, Hong J et al. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet 2012: 159B (5): 589-597.
4. Sellier C, Hagerman P, Willemsen R, Charlet-Berguerand N. DROSHA/DGCR8 sequestration by expanded CGG repeats leads to global micro-RNA processing alteration in FXTAS patients [abstract]. In 12th International Fragile X Conference. Detroit, MI, 2010.
5. Sellier C, Rau F, Liu Y et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 2010: 29 (7): 1248-1261.
6. Winarni TI, Chonchaiya W, Sumekar TA et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A 2012: 158A (10): 2473-2481.
7. Bourgeois JA, Coffey SM, Rivera SM et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009: 70 (6): 852-862.
8. Jacquemont S, Hagerman RJ, Leehey MA et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004: 291 (4): 460-469.
9. Coffey SM, Cook K, Tartaglia N et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008: 146A (8): 1009-1016.
10. Leehey MA, Berry-Kravis E, Min SJ et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007: 22 (2): 203-206.
11. Hamlin AA, Sukharev D, Campos L et al. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A 2012: 158A (6): 1304-1309.
12. Jacquemont S, Hagerman RJ, Leehey MA et al. Penetrance of the fragile X-associated tremor/ataxia syndrome (FXTAS) in a premutation carrier population: initial results from a California family-based study. In Am J Hum Genetics, 53rd Annual Meeting, Los Angeles, CA, 2003.
13. Soontarapornchai K, Maselli R, Fenton-Farrell G et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008: 65 (4): 495-498.
14. Grigsby J, Brega AG, Engle K et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008: 22 (1): 48-60.
15. Seritan AL, Nguyen DV, Farias ST et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008: 147B (7): 1138-1144.
16. Bourgeois J, Seritan A, Casillas E et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011: 72 (2): 175-182. DOI: 10.4088/JCP.09m05407blu, Published online by Physicians Postgraduate Press, Inc.
17. Roberts JE, Bailey DB Jr, Mankowski J et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009: 150B (1): 130-139.
18. Wittenberger MD, Hagerman RJ, Sherman SL et al. The FMR1 premutation and reproduction. Fertil Steril 2007: 87 (3): 456-465.
19. Hessl D, Tassone F, Loesch DZ et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 2005: 139B (1): 115-121.
20. Franke P, Leboyer M, Gansicke M et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res 1998: 80 (2): 113-127.
21. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 2009: 17 (10): 1359-1362.
22. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001: 41 (7): 646-657.
23. Mosewich R, Donat J, DiMauro S et al. The syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes presenting without stroke. Arch Neurol 1993: 50: 275-278.
24. Haan J, Terwindt GM, Maassen JA et al. Search for mitochondrial DNA mutations in migraine subgroups. Cephalalgia 1999: 19 (1): 20-22.
25. Silvestri G, Ciafaloni E, Santorelli F et al. Clinical features associated with the A->G transition at nucleotide 8344 of mtDNA. Neurology 1993: 43: 1200-1206.
26. Huoponen K. Leber hereditary optic neuropathy: clinical and molecular genetic findings. Neurogenetics 2001: 3 (3): 119-125.
27. Montagna P, Cortelli P, Barbiroli B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia 1994: 14 (3): 184-193.
28. Welch KM, Levine SR, D'Andrea G, Schultz LR, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989: 39 (4): 538-541.
29. Barbiroli B, Montagna P, Cortelli P et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992: 42 (6): 1209-1214.
30. Montagna P, Cortelli P, Monari L et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994: 44 (4): 666-669.
31. Ross-Inta C, Omanska-Klusek A, Wong S et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 2010: 429 (3): 545-552.
32. Napoli E, Ross-Inta C, Wong S et al. Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet 2011: 20 (15): 3079-3092.
33. Chen Y, Tassone F, Berman RF et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010: 19 (1): 196-208.
34. Tassone F, Hagerman RJ, Taylor AK et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000: 91 (2): 144-152.
35. Hessl D, Wang JM, Schneider A et al. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry 2011: 70 (9): 859-865.
36. Qin M, Entezam A, Usdin K et al. A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis. Neurobiol Dis 2011: 44 (3).
37. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004: 27 (7): 370-377.
38. D'Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 2007: 30 (8): 425-431.
39. Vikelis M, Mitsikostas DD. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007: 6 (4): 251-257.
40. Jacquemont S, Hagerman RJ, Leehey M et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003: 72 (4): 869-878.
41. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 2008: 10 (1): 43-49.
42. Tassone F, Hagerman RJ, Taylor AK et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000: 66 (1): 6-15.
43. Tietjen GE, Herial NA, Hardgrove J, Utley C, White L. Migraine comorbidity constellations. Headache 2007: 47 (6): 857-865.
44. Chinnery PF. Mitochondrial Disorders Overview. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, eds. GeneReviews™ [Internet]. Seattle, WA: University of Washington, 1993-2000, from http://www.ncbi.nlm.nih.gov/books/NBK1224/
45. Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004: 291 (4): 427-434.
46. Sas K, Pardutz A, Toldi J, Vecsei L. Dementia, stroke and migraine--some common pathological mechanisms. J Neurol Sci 2010: 299 (1-2): 55-65.
47. Yilmaz N, Karaali K, Ozdem S et al. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration? Cell Mol Neurobiol 2011: 31 (4): 579-585.
48. Vincent M, Hadjikhani N. The cerebellum and migraine. Headache 2007: 47 (6): 820-833.
49. Bourgeois JA, Seritan AL, Casillas EM et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011: 72 (2): 175-182.
50. Farmer K, Cady R, Bleiberg J et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 2001: 41 (4): 377-384.
51. Flippen C, Welch KM. Imaging the brain of migraine sufferers. Curr Opin Neurol 1997: 10 (3): 226-230.
52. Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990: 28 (6): 791-798.
53. Chonchaiya W, Au J, Schneider A et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet 2012: 131 (4): 581-589.
54. Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008: 146A (16): 2060-2069.
55. Roberts JE, Bailey DB Jr, Mankowski J et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009: 150B (1): 130-139.
56. Hamlin A, Liu Y, Nguyen DV et al. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet 2011: 156B (8): 923-928.
57. Conde V, Palomar FJ, Lama MJ et al. Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. J Neurophysiol 2012. DOI:10.1152/jn.00730.2012, Published online on 12 December 2012.
58. Stuart S, Griffiths LR. A possible role for mitochondrial dysfunction in migraine. Mol Genet Genomics 2012: 287 (11-12): 837-844. DOI: 10.1007/s00438-012-0723-7.
59. Welch KM, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci 1995: 134 (1-2): 9-14.
60. Welch KM. Current opinions in headache pathogenesis: introduction and synthesis. Curr Opin Neurol 1998: 11 (3): 193-197.
61. Montagna P, Sacquegna T, Martinelli P et al. Mitochondrial abnormalities in migraine. Preliminary findings. Headache 1988: 28 (7): 477-480.
62. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007: 83 (1): 84-92.
63. Casucci G, Villani V, Finocchi C. Therapeutic strategies in migraine patients with mood and anxiety disorders: physiopathological basis. Neurol Sci 2010: 31 (Suppl. 1): S99-S101.
64. Di Lorenzo C, Pierelli F, Coppola G et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 2009: 72 (18): 1588-1594.
65. Sangiorgi S, Mochi M, Riva R et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 1994: 14 (1): 21-23.
66. Littlewood J, Glover V, Sandler M et al. Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking. J Neurol Neurosurg Psychiatry 1984: 47 (4): 338-343.
67. Lodi R, Iotti S, Cortelli P et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001: 54 (4): 437-441.
68. Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2006: 26 (4): 361-372.
69. Cao Z, Hulsizer S, Tassone F et al. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet 2012: 21 (13): 2923-2935.
70. D'Andrea G, Leon A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol Sci 2010: 31 (Suppl. 1): S1-S7.
71. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008: 28 (11): 1170-1178.